Isotretinoin Step Therapy Policy
Defines a step therapy program for oral isotretinoin products administered by Cigna, designating Step 1 (preferred/generic and certain brands) and Step 2 (Absorica, Absorica LD) products and the criteria for coverage of Step 2 products. Approvals are for one year.
Policy reiterates that Absorica with DAW 9 counts as a Step 1 product.
Annual revision performed with no criteria changes.
Coverage Summary
Defines a step therapy program for oral isotretinoin products administered by Cigna, designating Step 1 (preferred/generic and certain brands) and Step 2 (Absorica, Absorica LD) products and the criteria for coverage of Step 2 products. Step 1 products are preferred first-line, and a trial of one Step 1 product is required before approval of a Step 2 product unless criteria are met. The policy notes that Absorica dispensed with DAW 9 counts as a Step 1 product. Approvals are provided for 1 year in duration.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.